Immatics (NASDAQ:IMTX) Stock Price Down 3.7%

Shares of Immatics (NASDAQ:IMTX) traded down 3.7% on Thursday . The stock traded as low as $10.62 and last traded at $10.69. 543,089 shares traded hands during trading, an increase of 3% from the average session volume of 526,042 shares. The stock had previously closed at $11.10.

Immatics Stock Performance

The company has a market cap of $889.78 million, a P/E ratio of -8.54 and a beta of 0.69. The firm has a 50 day moving average price of $11.75 and a two-hundred day moving average price of $10.57.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. BlackRock Inc. bought a new position in Immatics in the 1st quarter worth about $27,000. Tower Research Capital LLC TRC boosted its stake in Immatics by 224.9% in the 1st quarter. Tower Research Capital LLC TRC now owns 6,442 shares of the company’s stock worth $45,000 after purchasing an additional 4,459 shares during the period. Citigroup Inc. bought a new position in Immatics in the 2nd quarter worth about $46,000. UBS Group AG boosted its stake in Immatics by 230.3% in the 2nd quarter. UBS Group AG now owns 5,862 shares of the company’s stock worth $51,000 after purchasing an additional 4,087 shares during the period. Finally, Lazard Asset Management LLC bought a new position in Immatics in the 1st quarter worth about $84,000. Institutional investors own 64.41% of the company’s stock.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.